Clinical Data and Lab21 Launch Cardiac Channelopathy Genetic Test in United Kingdom & Ireland.

NEWTON, Mass. -- Clinical Data, Inc. (NASDAQ: CLDA) today announced that its PGxHealth[TM] division has entered into an agreement with Lab21, a leader in molecular diagnostic testing services in Europe. Under terms of this agreement, Lab21 will have exclusive rights in the U.K. and Ireland to market and sell Clinical Data's FAMILION([R]) test, a genetic test designed to identify mutations in people with inherited cardiac channelopathies such as Long QT Syndrome (LQTS) and Brugada Syndrome. In addition, the parties have agreed to consider other proprietary, molecular and pharmacogenomic tests developed and commercialized by PGxHealth for future launch in the U.K. and Ireland.

John Schultz, SVP, Business Development, PGxHealth, said, "This agreement enables Lab21, one of Europe's leading providers of molecular diagnostic tests, to exclusively market our Long QT genetic test, FAMILION, to end users in the United Kingdom and Ireland. PGxHealth's strong Long QT intellectual property portfolio (issued patents and pending applications), deep knowledge of the genetic foundation for these channelopathies, and experience with electrophysiologists and cardiologists will allow Lab 21 to offer providers and patients the best service and test offering for these cardiac channelopathies in their territory. Furthermore, our experience and proficiency in delivering this test will allow for an average of less than four weeks' turnaround time from sample receipt to delivery of test results. Consequently, we expect our combined offering with Lab21 to be highly competitive and address a significant unmet market need."

Berwyn Clarke, CSO of Lab21, said, "We are delighted to have the opportunity to exclusively provide PGxHealth's cardiac channelopathy test to customers in Ireland and the U.K. Lab21 already provides market leading genetic testing products particularly for predicting disease predisposition. This new relationship with PGxHealth offers us significant opportunities to build this franchise by leveraging our existing ties to many of the region's key healthcare providers. We look forward to exploring similar collaborations in the future as PGxHealth launches additional pharmacogenetic and molecular diagnostic tests."

For additional information on Lab21's Long QT test offering, please
contact Marc Southern.
[phone]
[e-mail]
www.lab-21.com

About Lab21 Ltd.

Lab21 Ltd. is an independent clinical services company which supports Healthcare providers and the pharmaceutical and biotechnology industries with technically advanced molecular services relating to personalised medicine and healthcare diagnostics.

The Lab21 team's experience and know-how is coupled with a rapidly growing portfolio of molecular diagnostics including pharmacogenetic and patient profiling tests, which all use cutting-edge technology. This unique combination adds value to early stage drug development, clinical trials and regulatory processes in the pharmaceutical industry -- and directly to clinicians or healthcare providers as they treat and monitor patients.

A portfolio of tests and services are available from the identification of a disease, predisposition to a disease, through to therapeutic monitoring. Lab21 Ltd offers full service from the provision of educational materials, the secure collection of patient samples, rapid test turnaround to clear interpretation of the results.

As we move towards truly personalised healthcare, the Lab21 team can contribute today - delivering high-quality information on drugs and patients that provides real clinical insight.

Internet Website: www.lab-21.com

About Clinical Data, Inc.

Clinical Data, Inc. is a global biotechnology company unlocking the potential of molecular discovery, from targeted science to better healthcare. Its PGxHealth division focuses on genetic test and biomarker development to help predict drug safety and efficacy, thereby reducing health care costs and improving clinical outcomes. Its Cogenics division provides molecular and pharmacogenomics services to both research and regulated environments. Its Vital Diagnostics division offers in vitro diagnostics solutions for the clinical laboratory. Through these divisions, Clinical Data is leveraging advances in molecular discovery to provide tangible benefits for patients, doctors, scientists and health plans worldwide.

About PGxHealth

PGxHealth[TM] has extensive experience and capabilities in the development, clinical validation and delivery of genomic-based tests, in particular in the areas of efficacy and safety biomarkers for appropriate drug utilization. Through its own know-how and resources, work conducted with some of the world's most prestigious genomics thought leaders and institutions, and use of innovative technologies, PGxHealth is focused on reducing treatment costs and improving clinical outcomes in those disease states and therapeutic classes beset with expensive, inefficient or suboptimal treatment options. It has branded its genetic tests based on these proprietary genetic markers Therapeutic Diagnostics[TM].

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This press release contains certain forward-looking information and statements that are intended to be covered by the safe harbor for forward looking statements provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)", "feel(s)", "believe(s)", "will", "may", "anticipate(s)" and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements about our ability to successfully integrate the operations, business, technology and intellectual property obtained in our recent acquisitions; our ability to obtain regulatory approval for, and successfully introduce our new products; our ability to expand our long-term business opportunities; our ability to maintain normal terms with our customers and partners; financial projections and estimates and their underlying assumptions; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, the effects of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, but are not limited to, whether Clinical Data will be able to develop or acquire additional products and attract new business and strategic partners; competition from pharmaceutical, biotechnology and diagnostics companies; the strength of our intellectual property rights; the effect on the Company's operations and results of significant acquisitions or divestitures made by major competitors; the Company's ability to achieve expected synergies and operating efficiencies in all of its acquisitions, and to successfully integrate its operations; and those risks discussed and identified by Clinical Data in its public filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. Clinical Data does not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Readers are also urged to carefully review and consider the various disclosures in Clinical Data's SEC reports, including but not limited to its Annual Report on Form 10-K for the fiscal year ended March 31, 2006, and fiscal 2005, 2006, and 2007 quarterly reports on Forms 10-QSB and 10-Q.

Internet Website: www.clda.com